Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction on Tuesday, October 20th. The shares were sold at an average price of $35.11, for a total value of $7,022,000.00. Following the sale, the chief executive officer owned 1,399,154 shares of the company’s stock, valued at approximately $49,124,296.94. The trade was a 12.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

• On Wednesday, September 30th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $36.62, for a total value of $7,324,000.00.
• On Friday, August 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $35.77, for a total value of $7,154,000.00.
• On Monday, July 27th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.95, for a total value of $6,990,000.00.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $37.45 on Friday. The stock has a market capitalization of $27.05 billion, a P/E ratio of -70.66 and a beta of 1.10. The stock’s fifty day moving average is $36.61 and its 200 day moving average is $33.32. Roivant Sciences Ltd. has a 52 week low of $17.89 and a 52 week high of $42.50.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The business had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Equities research analysts forecast that Roivant Sciences Ltd. will post -2.00 earnings per share for the current year.

Roivant Sciences News Roundup

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Brepocitinib met both Phase 3 primary endpoints. Roivant and Priovant reported that the CLARITY-1 and CLARITY-2 trials achieved their primary goals in non-infectious uveitis. The drug also delivered statistically significant and clinically meaningful improvements in key secondary measures, including sustained steroid-free disease control, reduced vascular leakage, resolution of macular edema and better patient-reported visual functioning. Roivant and Priovant announce positive brepocitinib Phase 3 results
• Positive Sentiment: The trial data could expand the drug’s commercial opportunity. Coverage highlighted brepocitinib’s ability to reduce reliance on steroids in inflammatory eye disease, while Roivant is expected to pursue a label expansion for Lisraya in uveitis. Positive commentary and analyst coverage contributed to the stock’s upward move. Roivant’s TYK2/JAK inhibitor reduces need for steroids
• Neutral Sentiment: Roivant will report fiscal second-quarter results on November 9, 2026. Investors will receive updated financial results and a business outlook, including any regulatory or commercialization plans related to brepocitinib. Roivant quarterly earnings announcement
• Negative Sentiment: CEO Eric Venker sold 200,000 shares worth approximately $7.0 million. The sale reduced his direct ownership by 12.5%, which may draw investor attention. However, it was executed under a pre-arranged Rule 10b5-1 trading plan, reducing its significance as a discretionary bearish signal. SEC insider transaction filing

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ROIV. Guggenheim boosted their target price on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. Citigroup reiterated a “buy” rating on shares of Roivant Sciences in a research report on Monday, October 12th. Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Finally, UBS Group set a $55.00 price objective on shares of Roivant Sciences in a research report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $45.64.

Institutional Trading of Roivant Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. Assenagon Asset Management S.A. boosted its stake in Roivant Sciences by 18.2% in the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock valued at $295,965,000 after buying an additional 1,286,464 shares in the last quarter. Perceptive Advisors LLC grew its position in Roivant Sciences by 3.8% in the first quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company’s stock valued at $229,507,000 after acquiring an additional 300,000 shares during the last quarter. Wellington Management Group LLP grew its position in Roivant Sciences by 179.0% in the second quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock valued at $95,124,000 after acquiring an additional 1,724,588 shares during the last quarter. Bank of America Corp DE raised its stake in Roivant Sciences by 8.0% during the first quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock worth $87,638,000 after acquiring an additional 235,493 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in Roivant Sciences by 6.1% during the first quarter. Janus Henderson Group PLC now owns 3,095,448 shares of the company’s stock worth $85,790,000 after acquiring an additional 177,339 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.